2/6
10:16 pm
rare
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
Neutral
Report
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
2/6
12:10 pm
rare
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Low
Report
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
2/6
11:41 am
rare
Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE)
Low
Report
Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE)
2/6
08:49 am
rare
RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Medium
Report
RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026
2/6
07:40 am
rare
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE
Medium
Report
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE
2/6
02:00 am
rare
RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.
Medium
Report
RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.
2/5
09:36 pm
rare
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Medium
Report
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
2/5
09:31 pm
rare
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
Medium
Report
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
2/5
04:57 pm
rare
ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. and Encourages Investors to Contact the Firm
Low
Report
ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. and Encourages Investors to Contact the Firm
2/5
04:05 pm
rare
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
Medium
Report
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
2/5
12:14 pm
rare
Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights
Medium
Report
Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights
2/5
12:00 pm
rare
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Medium
Report
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
2/5
11:57 am
rare
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
Low
Report
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
2/5
11:40 am
rare
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Medium
Report
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
2/5
07:20 am
rare
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
Low
Report
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
2/4
07:44 pm
rare
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law
Medium
Report
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law
2/4
07:28 pm
rare
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit
Medium
Report
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit
2/4
06:42 pm
rare
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Ultragenyx Pharmaceutical Inc. Common Stock and Sets a Lead Plaintiff Deadline of April 6, 2026
Medium
Report
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Ultragenyx Pharmaceutical Inc. Common Stock and Sets a Lead Plaintiff Deadline of April 6, 2026
2/3
02:08 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE
2/3
08:44 am
rare
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
2/3
08:00 am
rare
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Child
Low
Report
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Child
1/30
08:30 am
rare
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Low
Report
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
1/29
10:00 am
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/27
01:28 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Neutral
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
1/23
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)